EUVIMED · CrossrefJournal
Drug Metabolism and Pharmacokinetics
ISSN 1347-4367 · Elsevier BV
Latest articles
Assessment of infliximab biotransformation in patient serum by comparing mass-spectrometry and ligand-binding assay quantification
Translational limitations of a rat-derived hybrid pharmacokinetic–toxicodynamic model for chemotherapy-induced hematologic toxicity in humans
Microsomal and hepatocyte binding in drug discovery: Method suitability and lipophilicity-based predictions
UGT1A1 isoform-selective allosteric inhibition by dirithromycin
Impact of Membrane Permeability of P-glycoprotein Inhibitors on the Risk Assessment of Intestinal P-glycoprotein-Mediated Drug-Drug Interactions
Microfluidic post-insertion preparation and evaluation of RGD- and PEG-modified macrophage-derived small extracellular vesicles
Differences in reactive metabolite formation and cytochrome P450 binding between acetaminophen and its bicyclo[1.1.1]pentane bioisostere
Role of the arachnoid mater organic anion and cation transporters in the clearance of prostaglandin D2 and metformin from the cerebrospinal fluid in rats
A permeability assay adapted for the assessment of very poorly permeable compounds in the bRo5 space
Advances in In silico predictive models for DDI prediction: Implications and practical applications in drug discovery
Points to consider in the in vitro estimation of kinetic parameters for quantitative prediction of the drug-drug interactions caused by reversible inhibition of enzymes/transporters
Advances in DDI evaluations: Recent trends from pre-clinical studies to regulatory submissions
Glutathione-reversible inactivation of aldehyde oxidase by hydralazine contributes to inter-lot inhibition variability in human hepatocytes
K2-EDTA anticoagulant suppresses calcium-dependent paraoxonase 1-mediated hydrolysis in human plasma stability assays
β-Cyclodextrin as a Negative Allosteric Modulator of Mammea A/AA Binding to Serum Albumin: A Spectroscopic and Molecular Dynamics Study
Characterization of drug-drug interaction for antibody-drug conjugates and risk assessment using various approaches including physiologically based pharmacokinetic modeling
Applications of in vitro transporter assays for mechanistic characterization and prediction of clinical drug-drug interactions
Metabolism of simvastatin by Streptomyces griseolus CYP105A1 and its variants for the production of human simvastatin metabolites
Population pharmacokinetics of brexpiprazole in Japanese healthy subjects and patients with schizophrenia
Human aldo-keto reductase (AKR) 1C1 and 1C2 act as coactivators of pregnane X receptor, a master regulator of drug-metabolizing and gluconeogenesis enzymes
Drug-drug interaction between trastuzumab emtansine (T-DM1) and orally administered tacrolimus in a patient and in rats
Human brain organoids for understanding substance use disorders
Population pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia
Advancements in Microphysiological systems: Exploring organoids and organ-on-a-chip technologies in drug development -focus on pharmacokinetics related organs-
Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models
Sodium citrate buffer improves pazopanib solubility and absorption in gastric acid-suppressed rat model
Transcript abundance of hepatic drug-metabolizing enzymes in two dog breeds compared with 14 species including humans
Establishment of human intestinal organoids derived from commercially available cryopreserved intestinal epithelium and evaluation for pharmacokinetic study
Apple-derived extracellular vesicles modulate the expression of human intestinal bile acid transporter ASBT/SLC10A2 via downregulation of transcription factor RARα
High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database
EUVIMED